{"id":67,"date":"2025-08-27T09:28:04","date_gmt":"2025-08-27T09:28:04","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=67"},"modified":"2025-08-31T03:37:37","modified_gmt":"2025-08-31T03:37:37","slug":"china-bd-deal-fosun-and-sitala-enters-a-670-million-license-on-fxs6837","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/67.html","title":{"rendered":"[China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837"},"content":{"rendered":"\n<p>Announced Date: 2025-08-26 (August 26, 2025)<\/p>\n\n\n\n<p>Asset Name: FXS6837  \uff08Other code: XH-S003\uff09<\/p>\n\n\n\n<p>Licensor: Fosun Pharma and Fosun Pharma Industrial. (\u201cFosun Pharma\u201d; stock code: 600196.SH, 02196.HK) (Headquarter\uff0cShanghai, China)<\/p>\n\n\n\n<p>Licensee (Buyer): Sitala\uff08Sitala Bio Ltd\uff0cUK\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Target: Undisclosed&nbsp;Immune regulation disease target<\/p>\n\n\n\n<p>                                [CninMed &nbsp;surmise\uff1aComplement&nbsp;Factor&nbsp;B (CFB)\uff0cWO2022143940]<\/p>\n\n\n\n<p>Asset Modality: Small &nbsp;Molecule<\/p>\n\n\n\n<p>Current Stage: Phase II, China (IgA, PNH)<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Forsun has granted Sitala an exclusive license to develop, manufacture, and commercialize FXS6837 outside Great China<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp; $25 million;<\/p>\n\n\n\n<p>Development and regulatory milestone payments up to &nbsp;$165 million;<\/p>\n\n\n\n<p>Sales milestone payments of up to $480 million;<\/p>\n\n\n\n<p>Total up to $670 million.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Additional royalties based on net sales in the licensed territories.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Additionally, Fosun may acquire shares of Sitala valued at $5 million at zero consideration.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link: <a href=\"https:\/\/stockn.xueqiu.com\/02196\/20250826549847.pdf\">https:\/\/stockn.xueqiu.com\/02196\/20250826549847.pdf<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-08-26 (August 26, 2025) Asset Name: FXS6837 \uff08Other code: XH-S003\uff09 Licensor: Fosun Pharma and &hellip; <a title=\"[China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/67.html\"><span class=\"screen-reader-text\">[China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-67","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/67","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=67"}],"version-history":[{"count":9,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/67\/revisions"}],"predecessor-version":[{"id":94,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/67\/revisions\/94"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=67"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=67"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=67"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}